Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current issues in rectal cancer chemotherapy.

Mathew Joseph1, Al B Benson

  • 1Division of Hematology and Oncology, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA. mathew-joseph@northwestern.edu

Cancer Journal (Sudbury, Mass.)
|July 11, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consensus statements for the diagnosis of mild traumatic brain injury and clinical integration of blood-based biomarkers in the Asia-Pacific region: a modified Delphi study.

International journal of emergency medicine·2026
Same author

Beyond R2: Assessing quality of trial level surrogate endpoints in colorectal cancer.

Journal of the National Cancer Institute·2026
Same author

Gastrointestinal malignancies in pregnancy: practical considerations.

Journal of gastrointestinal oncology·2026
Same author

Trends in primary surgery and overall survival in non-metastatic anal cancer: a population-based analysis.

The oncologist·2026
Same author

Integrating oncology advanced practice providers and clinical pharmacists into clinical cancer research.

Journal of the National Cancer Institute·2026
Same author

Trends in primary surgery and overall survival in non-metastatic anal cancer: a population-based analysis.

The oncologist·2026

Chemotherapy improves outcomes for stage II and III rectal cancer by reducing recurrence and improving survival. Ongoing trials investigate new agents and molecular markers to personalize treatment and identify patients who may not need radiotherapy.

Area of Science:

  • Oncology
  • Gastrointestinal Oncology
  • Chemotherapy Research

Background:

  • Rectal cancer treatment involves complex decisions regarding adjuvant and neoadjuvant chemotherapy.
  • Risk stratification, using clinical and molecular factors, is crucial for treatment planning.
  • Understanding treatment-related symptomatology is vital for trial design and patient care.

Purpose of the Study:

  • To review studies on chemotherapy for stage II and III rectal cancer, focusing on adjuvant and neoadjuvant approaches.
  • To discuss the role of risk stratification, including clinical and molecular tumor analysis.
  • To examine rectal cancer symptomatology in treatment and explore novel therapeutic agents and ongoing clinical trials.

Main Methods:

  • A comprehensive MEDLINE search was conducted for clinical trials and reviews.

Related Experiment Videos

  • Relevant clinical trials on chemotherapy for rectal cancer were selected for analysis.

    • Main Results:

    • Adjuvant and neoadjuvant chemotherapy significantly reduce local recurrence rates and improve overall survival in rectal cancer.
    • Current trials are evaluating the effectiveness of oral fluoropyrimidines, novel platinum agents, and vascular endothelial growth factor inhibitors.

    Conclusions:

    • Ongoing large U.S. trials will clarify the efficacy of new chemotherapy agents and molecular markers in rectal cancer.
    • These trials will incorporate validated symptom assessments and molecular tumor marker evaluations.
    • Identifying low-risk patient groups who can avoid radiotherapy remains a key objective in rectal cancer management.